Hong Kong Drug Patent Portfolio
Hong Kong owns 1 orange book drug protected by 5 US patents Given below is the list of Hong Kong's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12121582 | Injectable pharmaceutical formulations of lefamulin | 14 Jun, 2036 | Active |
| US8071643 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | 25 Mar, 2033 | Active |
| US9120727 | Process for the preparation of pleuromutilins | 23 May, 2031 | Active |
| US8153689 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | 19 Mar, 2028 | Active |
| US6753445 | Pleuromutilin derivatives having antibacterial activity | 09 Jul, 2021 | Expired |
Latest Legal Activities on Hong Kong's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Hong Kong.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 02 Oct, 2023 | US8153689 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 23 May, 2023 | US8071643 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 22 Feb, 2023 | US9120727 |
|
Patent Term Extension Certificate
Critical
| 15 Feb, 2023 | US8071643 |
|
Withdrawal of Application for PTE
Critical
| 14 Feb, 2023 | US8153689 |
|
Withdrawal of Application for PTE
Critical
| 14 Feb, 2023 | US9120727 |
| Notice of Final Determination -Election Required | 05 Jan, 2023 | US9120727 |
| Notice of Final Determination -Election Required | 05 Jan, 2023 | US8153689 |
| Notice of Final Determination -Election Required | 05 Jan, 2023 | US8071643 |
| transaction for FDA Determination of Regulatory Review Period | 28 Sep, 2022 | US8071643 |
| transaction for FDA Determination of Regulatory Review Period | 28 Sep, 2022 | US8153689 |
| transaction for FDA Determination of Regulatory Review Period | 25 Sep, 2022 | US9120727 |
|
FDA Final Eligibility Letter
Critical
| 01 Aug, 2022 | US9120727 |
|
FDA Final Eligibility Letter
Critical
| 01 Aug, 2022 | US8153689 |
|
FDA Final Eligibility Letter
Critical
| 01 Aug, 2022 | US8071643 |
Hong Kong's Family Patents
Hong Kong Drug List
Given below is the complete list of Hong Kong's drugs and the patents protecting them.
1. Xenleta
Xenleta is protected by 5 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12121582 | Injectable pharmaceutical formulations of lefamulin |
14 Jun, 2036
(10 years from now)
| Active |
| US8071643 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
25 Mar, 2033
(7 years from now)
| Active |
| US9120727 | Process for the preparation of pleuromutilins |
23 May, 2031
(5 years from now)
| Active |
| US8153689 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
19 Mar, 2028
(2 years from now)
| Active |
| US6753445 | Pleuromutilin derivatives having antibacterial activity |
09 Jul, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xenleta's drug page